Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks

Ageing is a leading risk factor for many debilitating diseases. While age-related diseases have been the subject of over a century of intense investigation, until recently, physiological ageing was considered unavoidable. Pharmacological and genetic studies have since shown that ageing is a malleable process and that its abrogation can prevent its associated diseases. This review summarises a sample of the most promising efforts to deliver the products of ageing research to the clinic. Current efforts include the use of clinically approved drugs that have since been repurposed, as well as the development of novel therapeutics, to target ageing. Furthermore, ongoing research has sought reliable biomarkers of ageing that will accelerate the development of such therapeutics. Development of these technologies will improve quality of late-life and help relieve the enormous stress placed on state healthcare systems by a rapidly ageing global population. Thus, for both medical and socioeconomic reasons, it is imperative that ageing is made to yield to intervention. [Display omitted] •The rate of ageing is malleable and its suppression has potential to suppress disease.•Clinically approved therapeutics that act on ageing pathways could be repurposed to inhibit ageing.•Development of accurate biomarkers for ageing will increase the speed at which geroscience can be translated to the clinic.